Research Grade Adalimumab ( 阿达木单抗 )

CSD00093

Adalimumab

>95%

1mg/ml

PBS buffer PH7.5

CHO cells

Please contact with the lab for this information.

Adalimumab is a subcutaneously administered biological disease modifier for the treatment of rheumatoid arthritis and other chronic debilitating diseases mediated by tumor necrosis factor 2, 3. It was originally launched by Abbvie in the U.S. and approved in 2002 by the FDA 1. This drug is frequently known as Humira. It is produced by recombinant DNA technology using a mammalian cell expression system. This drug is available in a prefilled syringe form and convenient pen form for subcutaneous self-administered doses 1. A new biosesimilar to adalimumab, named adalimumab-adaz, was approved by the FDA on October 31, 2018. This biosesimilar is known as Hyrimoz, and is a trademark of Novartis AG 9.

D2E7

TNFSF2/TNF-alpha/TNFA[Homo sapiens]

Adalimumab (anti-TNF-alpha) blocks the interaction of TNF with the p55 and p75 cell surface TNF receptors, thereby neutralising the activity of this cytokine. Through its anti-TNF actions, adalimumab reduces concentrations of matrix metalloproteases (MMP-1 and -3) and other markers of cartilage and synovium turnover, reduces of matrix metalloproteases (MMP-1 and -3) and other markers of cartilage and synovium turnover, and reduces concentrations of acute phase reactants of inflammation (C-reactive protein [CRP] and erythrocyte sedimentation rate [ESR]) and serum cytokines (IL-1β mRNA, IL-1 receptor antagonist, IL-6).

Homo sapiens

IgG1-kappa

148000.00 Da

331731-18-1

For research use only .